220 related articles for article (PubMed ID: 18791055)
1. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.
Aletaha D; Landewe R; Karonitsch T; Bathon J; Boers M; Bombardier C; Bombardieri S; Choi H; Combe B; Dougados M; Emery P; Gomez-Reino J; Keystone E; Koch G; Kvien TK; Martin-Mola E; Matucci-Cerinic M; Michaud K; O'Dell J; Paulus H; Pincus T; Richards P; Simon L; Siegel J; Smolen JS; Sokka T; Strand V; Tugwell P; van der Heijde D; van Riel P; Vlad S; van Vollenhoven R; Ward M; Weinblatt M; Wells G; White B; Wolfe F; Zhang B; Zink A; Felson D
Ann Rheum Dis; 2008 Oct; 67(10):1360-4. PubMed ID: 18791055
[TBL] [Abstract][Full Text] [Related]
2. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.
Hellmich B; Flossmann O; Gross WL; Bacon P; Cohen-Tervaert JW; Guillevin L; Jayne D; Mahr A; Merkel PA; Raspe H; Scott DG; Witter J; Yazici H; Luqmani RA
Ann Rheum Dis; 2007 May; 66(5):605-17. PubMed ID: 17170053
[TBL] [Abstract][Full Text] [Related]
3. EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis.
Mankia K; Siddle HJ; Kerschbaumer A; Alpizar Rodriguez D; Catrina AI; Cañete JD; Cope AP; Daien CI; Deane KD; El Gabalawy H; Finckh A; Holers VM; Koloumas M; Ometto F; Raza K; Zabalan C; van der Helm-van Mil A; van Schaardenburg D; Aletaha D; Emery P
Ann Rheum Dis; 2021 Oct; 80(10):1286-1298. PubMed ID: 34362746
[TBL] [Abstract][Full Text] [Related]
4. Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology.
Buch MH; Silva-Fernandez L; Carmona L; Aletaha D; Christensen R; Combe B; Emery P; Ferraccioli G; Guillemin F; Kvien TK; Landewe R; Pavelka K; Saag K; Smolen JS; Symmons D; van der Heijde D; Welling J; Wells G; Westhovens R; Zink A; Boers M;
Ann Rheum Dis; 2015 Jun; 74(6):963-9. PubMed ID: 24827533
[TBL] [Abstract][Full Text] [Related]
5. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative.
Whittle SL; Colebatch AN; Buchbinder R; Edwards CJ; Adams K; Englbrecht M; Hazlewood G; Marks JL; Radner H; Ramiro S; Richards BL; Tarner IH; Aletaha D; Bombardier C; Landewé RB; Müller-Ladner U; Bijlsma JW; Branco JC; Bykerk VP; da Rocha Castelar Pinheiro G; Catrina AI; Hannonen P; Kiely P; Leeb B; Lie E; Martinez-Osuna P; Montecucco C; Ostergaard M; Westhovens R; Zochling J; van der Heijde D
Rheumatology (Oxford); 2012 Aug; 51(8):1416-25. PubMed ID: 22447886
[TBL] [Abstract][Full Text] [Related]
6. Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set.
Lage-Hansen PR; Svendsen N; Kirkham J; Nielsen SM; Amris K; de Wit M; Boers M; Ellingsen T; Christensen R
Ann Rheum Dis; 2024 May; ():. PubMed ID: 38777377
[TBL] [Abstract][Full Text] [Related]
7. EULAR recommendations for the involvement of patient research partners in rheumatology research: 2023 update.
de Wit M; Aouad K; Elhai M; Benavent D; Bertheussen H; Blackburn S; Böhm P; Duarte C; Falahee M; Karlfeldt S; Kiltz U; Mateus EF; Richards DP; Rodríguez-Carrio J; Sagen J; Shumnalieva R; Stones SR; Tas SW; Tillett W; Vieira A; Wilhelmer TC; Zabalan C; Primdahl J; Studenic P; Gossec L
Ann Rheum Dis; 2024 Jun; ():. PubMed ID: 38876509
[TBL] [Abstract][Full Text] [Related]
8. 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice.
Rodríguez-Carrio J; Burska A; Conaghan PG; Dik WA; Biesen R; Eloranta ML; Cavalli G; Visser M; Boumpas DT; Bertsias G; Wahren-Herlenius M; Rehwinkel J; Frémond ML; Crow MK; Rönnblom L; Versnel MA; Vital EM
Ann Rheum Dis; 2023 Jun; 82(6):754-762. PubMed ID: 36858821
[TBL] [Abstract][Full Text] [Related]
9. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.
Aletaha D; Landewe R; Karonitsch T; Bathon J; Boers M; Bombardier C; Bombardieri S; Choi H; Combe B; Dougados M; Emery P; Gomez-Reino J; Keystone E; Koch G; Kvien TK; Martin-Mola E; Matucci-Cerinic M; Michaud K; O'Dell J; Paulus H; Pincus T; Richards P; Simon L; Siegel J; Smolen JS; Sokka T; Strand V; Tugwell P; van der Heijde D; van Riel P; Vlad S; van Vollenhoven R; Ward M; Weinblatt M; Wells G; White B; Wolfe F; Zhang B; Zink A; Felson D; ;
Arthritis Rheum; 2008 Oct; 59(10):1371-7. PubMed ID: 18821648
[TBL] [Abstract][Full Text] [Related]
10. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.
Felson DT; Smolen JS; Wells G; Zhang B; van Tuyl LH; Funovits J; Aletaha D; Allaart CF; Bathon J; Bombardieri S; Brooks P; Brown A; Matucci-Cerinic M; Choi H; Combe B; de Wit M; Dougados M; Emery P; Furst D; Gomez-Reino J; Hawker G; Keystone E; Khanna D; Kirwan J; Kvien TK; Landewé R; Listing J; Michaud K; Martin-Mola E; Montie P; Pincus T; Richards P; Siegel JN; Simon LS; Sokka T; Strand V; Tugwell P; Tyndall A; van der Heijde D; Verstappen S; White B; Wolfe F; Zink A; Boers M
Ann Rheum Dis; 2011 Mar; 70(3):404-13. PubMed ID: 21292833
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
Tabernero J; Garcia-Carbonero R; Cassidy J; Sobrero A; Van Cutsem E; Köhne CH; Tejpar S; Gladkov O; Davidenko I; Salazar R; Vladimirova L; Cheporov S; Burdaeva O; Rivera F; Samuel L; Bulavina I; Potter V; Chang YL; Lokker NA; O'Dwyer PJ
Clin Cancer Res; 2013 May; 19(9):2541-50. PubMed ID: 23532888
[TBL] [Abstract][Full Text] [Related]
12. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA.
Hecht C; Englbrecht M; Rech J; Schmidt S; Araujo E; Engelke K; Finzel S; Schett G
Ann Rheum Dis; 2015 Dec; 74(12):2151-6. PubMed ID: 25115448
[TBL] [Abstract][Full Text] [Related]
13. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs.
Radner H; Smolen JS; Aletaha D
Arthritis Res Ther; 2014 Feb; 16(1):R56. PubMed ID: 24555808
[TBL] [Abstract][Full Text] [Related]
14. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
Smolen JS; Landewé R; Bijlsma J; Burmester G; Chatzidionysiou K; Dougados M; Nam J; Ramiro S; Voshaar M; van Vollenhoven R; Aletaha D; Aringer M; Boers M; Buckley CD; Buttgereit F; Bykerk V; Cardiel M; Combe B; Cutolo M; van Eijk-Hustings Y; Emery P; Finckh A; Gabay C; Gomez-Reino J; Gossec L; Gottenberg JE; Hazes JMW; Huizinga T; Jani M; Karateev D; Kouloumas M; Kvien T; Li Z; Mariette X; McInnes I; Mysler E; Nash P; Pavelka K; Poór G; Richez C; van Riel P; Rubbert-Roth A; Saag K; da Silva J; Stamm T; Takeuchi T; Westhovens R; de Wit M; van der Heijde D
Ann Rheum Dis; 2017 Jun; 76(6):960-977. PubMed ID: 28264816
[TBL] [Abstract][Full Text] [Related]
15. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.
Smolen JS; Breedveld FC; Burmester GR; Bykerk V; Dougados M; Emery P; Kvien TK; Navarro-Compán MV; Oliver S; Schoels M; Scholte-Voshaar M; Stamm T; Stoffer M; Takeuchi T; Aletaha D; Andreu JL; Aringer M; Bergman M; Betteridge N; Bijlsma H; Burkhardt H; Cardiel M; Combe B; Durez P; Fonseca JE; Gibofsky A; Gomez-Reino JJ; Graninger W; Hannonen P; Haraoui B; Kouloumas M; Landewe R; Martin-Mola E; Nash P; Ostergaard M; Östör A; Richards P; Sokka-Isler T; Thorne C; Tzioufas AG; van Vollenhoven R; de Wit M; van der Heijde D
Ann Rheum Dis; 2016 Jan; 75(1):3-15. PubMed ID: 25969430
[TBL] [Abstract][Full Text] [Related]
16. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis.
Matcham F; Scott IC; Rayner L; Hotopf M; Kingsley GH; Norton S; Scott DL; Steer S
Semin Arthritis Rheum; 2014 Oct; 44(2):123-30. PubMed ID: 24973898
[TBL] [Abstract][Full Text] [Related]
17. The Real-World Effectiveness, Persistence, Adherence, and Safety of Janus Kinase Inhibitor Baricitinib in Rheumatoid Arthritis: A Long-Term Study.
Calvo-Garcia A; Ramírez Herráiz E; Llorente Cubas IM; Varas De Dios B; Benedí González J; Morell Baladrón A; García-Vicuña R
J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38731045
[No Abstract] [Full Text] [Related]
18. Design an Intervention Study.
Ishizaki J; Hasegawa H
Methods Mol Biol; 2024; 2766():317-324. PubMed ID: 38270891
[TBL] [Abstract][Full Text] [Related]
19. Ten-year radiographic and functional outcomes in rheumatoid arthritis patients in remission compared to patients in low disease activity.
Ruyssen-Witrand A; Guernec G; Dupont J; Lapuyade D; Lioté F; Vittecoq O; Degboé Y; Constantin A
Arthritis Res Ther; 2023 Oct; 25(1):207. PubMed ID: 37864239
[TBL] [Abstract][Full Text] [Related]
20. Fatigue in patients with rheumatic and musculoskeletal diseases: a scoping review on definitions, measurement instruments, determinants, consequences and interventions.
Beckers E; Hermans K; Van Tubergen A; Boonen A
RMD Open; 2023 Aug; 9(3):. PubMed ID: 37541741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
